Valkal Bhatt

595 total citations
46 papers, 383 citations indexed

About

Valkal Bhatt is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Valkal Bhatt has authored 46 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 13 papers in Oncology and 9 papers in Genetics. Recurrent topics in Valkal Bhatt's work include Hematopoietic Stem Cell Transplantation (19 papers), Acute Lymphoblastic Leukemia research (8 papers) and Lymphoma Diagnosis and Treatment (6 papers). Valkal Bhatt is often cited by papers focused on Hematopoietic Stem Cell Transplantation (19 papers), Acute Lymphoblastic Leukemia research (8 papers) and Lymphoma Diagnosis and Treatment (6 papers). Valkal Bhatt collaborates with scholars based in United States, Germany and Spain. Valkal Bhatt's co-authors include Sergio Giralt, Alex Ganetsky, Miguel‐Angel Perales, Molly Maloy, Vivek Roy, Juliet N. Barker, Michael Scordo, Sean M. Devlin, Jie Yang and Esperanza B. Papadopoulos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Valkal Bhatt

37 papers receiving 378 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Valkal Bhatt United States	12	145	135	127	70	69	46	383
Yuichiro Nawa Japan	10	70 0.5×	101 0.7×	145 1.1×	68 1.0×	88 1.3×	32	337
Mathieu Puyade France	12	90 0.6×	154 1.1×	87 0.7×	53 0.8×	134 1.9×	57	461
Ayşegül Ünüvar Türkiye	13	82 0.6×	66 0.5×	135 1.1×	47 0.7×	59 0.9×	55	436
Ernesta Audisio Italy	12	93 0.6×	159 1.2×	174 1.4×	52 0.7×	92 1.3×	36	402
Giulio Trapè Italy	10	73 0.5×	107 0.8×	93 0.7×	68 1.0×	69 1.0×	15	294
Pınar Ataca Atilla Türkiye	9	97 0.7×	186 1.4×	200 1.6×	45 0.6×	24 0.3×	18	383
Chiara Savignano Italy	11	59 0.4×	159 1.2×	166 1.3×	45 0.6×	88 1.3×	27	381
Odelia Amit Israel	13	44 0.3×	278 2.1×	167 1.3×	97 1.4×	91 1.3×	39	525
L. S. Zubarovskaya Russia	9	64 0.4×	62 0.5×	126 1.0×	78 1.1×	23 0.3×	140	297
Toshimitsu Ueki Japan	10	220 1.5×	162 1.2×	128 1.0×	64 0.9×	25 0.4×	43	390

Countries citing papers authored by Valkal Bhatt

Since Specialization

Citations

This map shows the geographic impact of Valkal Bhatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valkal Bhatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valkal Bhatt more than expected).

Fields of papers citing papers by Valkal Bhatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valkal Bhatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valkal Bhatt. The network helps show where Valkal Bhatt may publish in the future.

Co-authorship network of co-authors of Valkal Bhatt

This figure shows the co-authorship network connecting the top 25 collaborators of Valkal Bhatt. A scholar is included among the top collaborators of Valkal Bhatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valkal Bhatt. Valkal Bhatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Salhotra, Amandeep, et al.. (2025). Axatilimab in Patients With Lung Chronic Graft-versus-Host Disease and Related Bronchiolitis Obliterans Syndrome: Results from the AGAVE-201 Study. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A5236–A5236.

Vachhani, Pankit, et al.. (2025). MPN-993: Clinical Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib and Anemia-Supporting Medications. Clinical Lymphoma Myeloma & Leukemia. 25. S683–S683.

Farhadfar, Nosha, et al.. (2025). Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study. Blood. 146(Supplement 1). 272–272.

Kitko, Carrie L., Amandeep Salhotra, Mi Kwon, et al.. (2025). Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201. Blood. 146(Supplement 1). 6010–6010.

Vachhani, Pankit, et al.. (2024). Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications. Blood. 144(Supplement 1). 4546–4546. 1 indexed citations

Mahmoudjafari, Zahra, Valkal Bhatt, John P. Galvin, et al.. (2024). Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease. Bone Marrow Transplantation. 60(1). 69–78. 1 indexed citations

Yu, Jingbo, Nandita Khera, James Turnbull, et al.. (2023). Impact of Chronic Graft-versus-Host Disease on Patient Employment, Income, and Informal Caregiver Burden: Findings From the Living With Chronic GVHD Patient Survey. Transplantation and Cellular Therapy. 29(7). 470.e1–470.e9. 6 indexed citations

Gerds, Aaron T., Michael R. Grunwald, Stephen T. Oh, et al.. (2023). P1032: CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL. HemaSphere. 7(S3). e48080f5–e48080f5. 1 indexed citations

Schroeder, Mark A., et al.. (2022). Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. Bone Marrow Transplantation. 57(6). 975–981. 7 indexed citations

10.

Bell, Elizabeth J., Jingbo Yu, Valkal Bhatt, et al.. (2022). Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease. Transplantation and Cellular Therapy. 28(10). 707.e1–707.e7. 6 indexed citations

11.

Lee, Stephanie J., Franco Locatelli, Francis Ayuk, et al.. (2021). Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT). Blood. 138(Supplement 1). 3909–3909. 1 indexed citations

12.

Gutgarts, Victoria, Insara Jaffer Sathick, Junting Zheng, et al.. (2020). Incidence and Risk Factors for Acute and Chronic Kidney Injury after Adult Cord Blood Transplantation. Biology of Blood and Marrow Transplantation. 26(4). 758–763. 11 indexed citations

13.

Lin, Andrew, Molly Maloy, Yiqi Su, et al.. (2019). Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experience. Transplant Infectious Disease. 21(6). e13187–e13187. 65 indexed citations

14.

Scordo, Michael, Valkal Bhatt, Patrick Hilden, et al.. (2019). Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 25(8). 1526–1535. 17 indexed citations

15.

Bhatt, Valkal. (2018). Current market and regulatory landscape of biosimilars.. PubMed. 24(21 Suppl). S451–S456. 5 indexed citations

16.

Shah, Gunjan L., Andrew Lin, Ryan Schofield, et al.. (2017). Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT). Blood. 130. 2023–2023. 2 indexed citations

17.

Shah, Gunjan L., Heather Landau, Ryan Schofield, et al.. (2017). Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis. Blood. 130. 3296–3296. 2 indexed citations

18.

Scordo, Michael, Valkal Bhatt, Meier Hsu, et al.. (2016). A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biology of Blood and Marrow Transplantation. 23(1). 38–43. 16 indexed citations

19.

Shah, Gunjan L., Leyla Shune, Duncan Purtill, et al.. (2015). Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. Biology of Blood and Marrow Transplantation. 21(12). 2160–2166. 30 indexed citations

20.

Dahi, Parastoo B., Roni Tamari, Sean M. Devlin, et al.. (2014). Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 20(12). 2004–2009. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact